Nuvation Bio Inc. announced the completion of its business combination with Panacea Acquisition Corp. The resulting combined company will commence trading its shares on the New York Stock Exchange (NYSE) under the ticker symbol "NUVB" on February 11, 2021. The business combination was approved by Panacea's shareholders on February 9, 2021 and was previously approved by Nuvation Bio shareholders.

Nuvation Bio's management team will lead the combined company, with founder David Hung, M.D., serving as chief executive officer.